Related Experiment Video
Updated: May 27, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
[Factors linked to adhesion to treatment in patients with refractory and non-refractory epilepsy]
Pedro Jesús Serrano-Castro1, Carmen Pozo-Muñoz, Enrique Alonso-Morillejo
1Unidad de Neurología y Neuro-fisiología, Hospital Torrecárdenas, Almería, España. pedro.serrano.c@gmail.com
Introduction:
Non-compliance with therapy is a problem in clinical practice in chronic diseases. Nevertheless, there are important gaps in our knowledge on this subject and its associated factors in patients with epilepsy. Moreover, failure to comply could lead to poor classification of the patients according to the definition of refractory epilepsy.
Aims:
To examine the behaviour in terms of therapy compliance and the clinical, psychosocial and developmental factors involved in a group of patients with epilepsy, and also to analyse the differences in the psychosocial variables depending on the degree of resistance.
Patients And Methods:
The study involved 112 epileptic patients recruited consecutively in the epilepsy unit of a tertiary health care centre. Patients were administered a questionnaire designed to collect sociodemographic and clinical variables, together with data about treatment, adhesion, reasons for non-compliance, social support, health, welfare and degree of response to treatment.
Results:
The levels of non-compliance with therapy agreed with those found in previous studies. No significant differences in the level of adhesion were found between patients with refractory epilepsy and pharmacologically-controlled epilepsy, although significant differences were observed in the level of health, welfare, social support and other associated variables.
Conclusions:
The level of compliance of epileptic patients is rather poor. Patients with refractory epilepsy are more aware of the severity of their disease, they are more critical with the health care system and with their social setting, and they tend to comply better with their treatment. Hence, there are no reasons to believe that therapy non-compliance can explain a high proportion of the resistance that exists in epilepsy.
More Related Videos
09:32Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
Published on: December 18, 2016
09:07Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Epilepsy ll: Types
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...